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Abstract
Background: Probiotics are widely used to improve gastrointestinal (GI) health, but they may also be useful to
prevent or treat gynaecological disorders, including bacterial vaginosis (BV) and candidiasis. BV prevalence is high
in South Africa and is associated with increased HIV risk and pregnancy complications. We aimed to assess the
availability of probiotics for vaginal health in retail stores (pharmacies, supermarkets and health stores) in two major
cities in South Africa.
Methods: A two-stage cluster sampling strategy was used in the Durban and Cape Town metropoles. Instructions
for use, microbial composition, dose, storage and manufacturers’ details were recorded.
Results: A total of 104 unique probiotics were identified in Cape Town and Durban (66.4% manufactured locally).
Cape Town had more products than Durban (94 versus 59 probiotics), although 47% were common between cities
(49/104). Only four products were explicitly for vaginal health. The remainder were for GI health in adults (51.0%) or
infants (17.3%). The predominant species seen overall included Lactobacillus acidophilus (53.5%), L. rhamnosus (37.6%),
Bifidobacterium longum ssp. longum (35.6%) and B. animalis ssp. lactis (33.7%). Products for vaginal health contained
only common GI probiotic species, with a combination of L. acidophilus/B. longum ssp. longum/B. bifidum, L.
rhamnosus/L. reuteri or L. rhamnosus alone, despite L. crispatus, L. gasseri, and L. jensenii being the most
common commensals found in the lower female reproductive tract.
Conclusion: This survey highlights the paucity of vaginal probiotics available in South Africa, where vaginal
dysbiosis is common. Most vaginal products contained organisms other than female genital tract commensals.
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Background
Maintenance of vaginal health is thought to play an im-
portant role in protecting women from reproductive
complications and the acquisition of sexually transmitted
infections (STIs) [1–10]. A healthy vagina is generally
thought to be defined as one with a low pH and a Lacto-
bacillus spp. dominance. Commensal Lactobacillus spp.
in the genital tract have been thought to contribute to
genital health by their ability to lower vaginal pH, to
produce bactericidal compounds, and to competitively
outcompete potentially pathogenic bacteria [8, 11–14].
A healthy lower female reproductive tract is dominated
by various Lactobacillus spp., with L. crispatus, L. gasseri,
L. jensenii, L. iners and L. vaginalis the most frequent and
abundant organisms present in North American women
[8, 9]. Several studies have shown that the predominant
bacterial species colonizing the female genital tract differ
by geography and ethnicity [8]. Only 37% of asymptomatic
South African women had a Lactobacillus spp. dominant
vaginal microbiome compared to 90% of white and 62% of
black women in developed countries [8, 15, 16]. Within
North American women, Lactobacillus predominance
differed by ethnic group, with 89.7% of white and 80.2% of
Asian women having a genital tract dominated by L.
crispatus, L. gasseri, L. iners and L. jensenii. Only 61.9% of
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black and 59.6% of Hispanic women showed a similar pat-
tern [8]. In South Africa the predominant Lactobacillus
spp. found in young women in KwaZulu Natal was L.
iners, which differs from the species described in the
female genital tracts of North American women [15].
Depletion of commensal Lactobacillus spp., an increase
in bacterial diversity and an overgrowth of pathogenic
bacteria are associated with the development of bacterial
vaginosis (BV) [17]. Although not considered a STI, BV is
the most prevalent condition to influence vaginal health
in women of reproductive age, and is considered to be en-
hanced by sexual activity [18]. It increases risk of endo-
metritis, preterm delivery, chorioamnionitis, spontaneous
abortion, maternal/neonatal sepsis [1–3, 19–21] and sus-
ceptibility to viral (including HIV, HPV and HSV-2) or
bacterial (including Trichomonas vaginalis, Neisseria
gonorrhoeae and Chlamydia trachomatis) infections [4–7,
22, 23]. Its prevalence varies both between and within
countries and is thought to be influenced by host genetics
and social factors [24]. The prevalence is the lowest in
Asia and Europe (4.5 to 24%) and highest in Sub-Saharan
Africa (SSA; 6 to 58%) [25]. The high rates in SSA and the
association with a more than three-fold increase in HIV
transmission in a region bearing the burden of HIV un-
derlines the urgent need for effective treatment [26].
Despite these serious adverse outcomes, few effective
strategies to manage BV and its recurrence exist. Identi-
fying women with BV is challenging as most cases are
asymptomatic [27, 28]. Furthermore, antibiotic treat-
ment of BV, the current standard of care, results in only
a temporary decrease in dysbiosis with high recurrence
rates. Approximately 30% of cases recur within
three months of treatment and 50% within six months
[29]. Studies that investigated the efficacy of probiotics
in the treatment of BV have mostly reported improved
cure and no adverse events [30, 31]. However, there is
substantial heterogeneity between these trials, with dif-
ferences in bacterial species and strains used, dose and
duration of treatment, route of administration, and
population studied.
Probiotics are defined as “live microorganisms, that,
when administered in adequate amounts, confer a health
benefit on the host” [32]. The bacteria typically con-
tained in probiotics include a diverse spectrum of Lacto-
bacillus spp. (including L. rhamnosus, L. casei, L.
acidophilus and L. plantarum) and Bifidobacterium spp.
(including B. breve, B. bifidum, B. infantis and B. ani-
malis), which colonize the healthy human gastrointes-
tinal tract (GIT) [33]. Additionally, yeast strains such as
Saccharomyces cerevisiae or S. boulardii are sometimes
included into formulation [33]. Probiotics have been
used to treat or prevent disorders of the GIT and im-
mune system in both adults and infants [34, 35]. Probio-
tics are also used to maintain vaginal health, including
for the treatment of BV [30]. In order for the probiotic
bacteria to positively impact vaginal health, they first
need to colonize the female genital tract successfully.
For a successful colonization and the ability to confer a
health benefit to the host, the bacteria need to fulfil vari-
ous criteria including: adherence to vaginal epithelial
cells, production of hydrogen peroxide, bacteriocins and
biosurfactant, restoration of vaginal pH, and inhibition
of potential pathogens associated with BV [36].
Probiotics for vaginal health have been administered
vaginally and orally. Oral probiotics were first considered
in 2001, when it was shown that probiotic bacteria can
passively move from the rectum to the female genital
tract [37, 38]. Oral administration of a two strain com-
bination of L. rhamnosus GR-1® and L. reuteri RC-14®
was shown to increase the level of those species in stool
and in the vagina, supporting the notion of ano-vaginal
transfer [39]. An oral daily dose of over one billion
colony-forming units (cfu) maintained a Lactobacillus-
dominated vaginal microbiome [37]. Additionally, it has
been suggested that oral probiotics may inhibit the ano-
vaginal transfer of yeast and pathogenic bacteria [40].
However, the level of probiotic bacteria delivered by oral
administration is lower than following vaginal adminis-
tration [41]. Importantly, the time required to affect
vaginal health is longer with oral than direct vaginal ad-
ministration and depends on the viability of the bacteria
after they pass through the GIT [39].
Probiotics are often administered along with prebiotics
(then called synbiotics) as this is thought to selectively
support the growth of probiotic microbiota, thereby in-
creasing their persistence [42, 43]. Commonly used pre-
biotics are short-chain carbohydrates, particularly inulin,
oligosaccharides and pyrodextrins, which are resistant to
digestion, fermentable by intestinal microbes and sup-
port the selective growth of administered bacteria [33].
The global probiotic market was reported to be USD
27.9 billion in 2011, with an estimated annual growth of
6.8% (http://www.nutraingredients.com/Markets-and-
Trends/Global-probiotics-market-to-grow-6.8-annually-
until-2018). This rapid growth has created the need for
effective legislative regulations of probiotics. The
United States Food and Drug Administration (FDA)
states that probiotics may be regulated as dietary supple-
ments, conventional food or meal replacement, or as
drugs depending on their intended use (http://
www.fda.gov/regulatoryinformation/guidances/
ucm144657.htm). Similarly, the South African Medi-
cines Control Council (MCC) classifies probiotic-
containing products either as complementary medicine or
as medicines when making medicinal claims or contain-
ing ≥ 1 × 109 cfu per dose unit (http://www.mccza.com/
Publications). Despite this, probiotics are not included in
the treatment covered by some of the largest medical
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insurance companies in South Africa (Fedhealth, Boni-
tas and Momentum).
The aim of this survey was to review probiotics avail-
able on the South African retail market and evaluate




A cross-sectional survey by means of a two-stage cluster
sampling was conducted in Durban and Cape Town,
South Africa, between September 2015 and January
2016. The primary clusters were geographically demar-
cated and consisted of the seven and eight districts con-
stituting the Durban and Cape Town metropoles,
respectively. The secondary clusters were the major
shopping malls in each of the respective districts. Details
on all probiotic products in every store retailing probio-
tics, including pharmacies, health stores and supermar-
kets in the major shopping mall servicing each of the
seven districts making up the Durban metropole [Cen-
tral (The Workshop, City Centre), Outer West (Hillcrest
Centre, Hillcrest), South (Galleria Centre, Amanzimtoti),
South Central (Chatsworth Centre, Chatsworth), Inner
West (The Pavillion, Westville), North Central (Bluff
Centre, Bluff ) and North (Gateway Centre, Mt. Edge-
combe)] and the eight districts making up the Cape
Town metropole [South (Blue Route Centre, Tokai),
South Peninsula (Long Beach Mall, Fishhoek/Kommet-
jie), Atlantic Seaboard (Cape Quarter, Greenpoint),
City Bowl (V&A, Waterfront), West Coast (Bayside
Mall, Bloubergstrand), North (Canal Walk Mall, Cen-
tury City), Cape Flats (Liberty Promenade, Mitchells
Plain) and Helderberg (Waterstone Centre, Somerset
West)] were collected (Fig. 1a and b). The following
characteristics were captured: formulation (tablet, pow-
der or liquid), composition (strains, number of viable
cells/cfu, presence/absence of prebiotics, additional in-
gredients), target population (general, women, infants),
storage (room temperature, refrigerated), price, expiry
date, recommended mode of administration, medicinal
claims and manufacturers' details.
Data capture and analysis
Product characteristics were electronically captured in a
spread sheet. Statistical analysis was conducted using
STATATM version 12 (StataCorp, College Station, TX,
USA). Descriptive measures (mean, median, frequencies
and percentages) were used to summarize the data. The
shelf life of products was estimated by calculating the
time difference between time of survey and expiry date
of the product.
Results
A total of 104 unique probiotic products were surveyed
from South Africa (SA), with 94 available in Cape Town
and 59 in Durban. Forty-five products were only found
in Cape Town, ten were only available in Durban, and
49 products were common to both cities (Fig. 1d). Pro-
biotic range differed by district, with the eight Cape Town
districts averaging 37 distinct products per district [highest
(64) in the Northern suburbs and the lowest (13) in the
Atlantic Seaboard] (Fig. 1a). The seven districts of Durban
averaged 16 distinct products per district [highest (30) in
the Outer West district to the lowest (5) in the Southern
district] (Fig. 1b).
Of the 104 probiotics identified, more than half (51%)
had GIT health claims for adults and 17% were indicated
for GIT and skin conditions in infants. Less than 10% of
the probiotic products had claims in multiple health cat-
egories such as GIT and immunological health. Medicinal
claims of probiotics in both cities were similar (Fig. 1c).
Less than 4% of probiotics in both cities in SA (4/104; in-
cluding Provacare® Probiotic Vaginal Care, Reuterina™
Femme, UltraFlora® Women’s, Vagiforte® Plus) were expli-
citly for vaginal health (Fig. 1c).
Bacterial species included in probiotic formulations
The most common bacterial species found in the pro-
biotics belonged to the genera Lactobacillus [15 species;
most commonly L. acidophilus (in 53.5% of the recorded
products), L. rhamnosus (37.6%), L. plantarum (19.8%)]
and Bifidobacterium [8 species; most commonly B.
longum ssp. longum (35.6%), B. animalis ssp. lactis
(33.7%), B. bifidum (26.7%)] (Fig. 2a). The most common
combinations of species were L. acidophilus with B.
longum ssp. longum (in 24 products), L. acidophilus with
B. bifidum (23 products), B. longum ssp. longum with B.
bifidum (23 products), L. acidophilus with L. rhamnosus
(19 products), and L. rhamnosus with B. longum ssp.
longum (18 products) (Fig. 2b, Additional file 1: Figure
S1.1 and Additional file 2: Figure S1.2). Other less com-
mon organisms contained in probiotics were Saccharo-
myces boulardii and S. cerevisiae, Streptococcus
thermophilus, Enterococcus mundtii, Lactococcus lactis
and Propionibacterium shermanii.
The vaginal probiotics contained either a combination
of the three species L. acidophilus/B. longum ssp.
longum/B. bifidum (Bioflora Vagiforte® Plus), two species
L. rhamnosus/L. reuteri (Reuterina™ Femme, UltraFlora®
Women’s) or the single bacterial species L. rhamnosus
(Provacare® Probiotic Vaginal Care).
Dose, formulation and storage
The number of bacterial strains contained per product
ranged from 1 (25.0%, 26/104) to 12 (2.9%, 3/104) with a
mean of 3. Overall, probiotic products claimed to
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contain a median of 1.5 × 109 viable organisms ranging
from 4 × 107 to 9 × 1011 cfu per dose, with daily dosage
recommended. The daily dose (capsules per day) of prod-
ucts depended on therapeutic indication: prophylaxis
(chronic), treatment (acute) or as an adjunct to antibiotic
treatment. However, organisms included in these different
probiotic preparations did not differ according to indica-
tion. Interestingly, some products formulated with exactly
the same bacterial species, strains and cfu were marketed
by different manufacturers under both similar and mul-
tiple health claims (Additional file 1: Figure S1.1 and Add-
itional file 2: Figure S1.2). Others contained the same
bacterial species but with different doses of each species
(e.g., two species combination L. acidophilus/B. ani-
malis ssp. lactis: range 5 × 108 to 15 × 109 cfu or single
species L. sporogenes: range 4 × 107 to 6 × 109 cfu). In
some instances the same manufacturer produced a
range of probiotic products with identical bacterial
Fig. 1 The South African probiotic market. Availability of probiotics by districts in the Cape Town (a) and Durban (b) metropoles. Cape Town
consists of eight districts while Durban metropole is made up of seven districts. A colour scale was used to denote variation in the number of
distinct probiotics available for each district. c Usage of probiotics. Each product was grouped into one of six categories according to their health
claim; and the overall or city-specific distribution is depicted by the stacked bars. d Market share Cape Town vs. Durban. The area proportional Venn
diagram represents the number of probiotics marketed exclusively in Cape Town (purple) or Durban (light blue) and those common to both
cities (blue)
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strain content and dose while marketing them as dis-
tinct products with different health claims (Additional
file 1: Figure S1.1 and Additional file 2: Figure S1.2).
The most common formulation was capsules (59.8%),
with some products available as liquids (18.7%), tablets
(13.1%) or powder (8.4%). The majority (82.7%, 86/104)
were stored on the shelf (room temperature), and 17.3%
(18/104) were stored in the fridge (4 °C). Probiotics
maintained at 4 °C tended to be from the same manufac-
turer (10/18 produced by Metagenics® and 5/18 produced
by Bioflora CC), but did not appear to be systematically
different in formulation, probiotic composition or expiry
date. The average shelf life time was 14 months (from time
of survey to recorded product expiry date) for both prod-
ucts stored at room temperature and at 4 °C. There was
no correlation between shelf life and formulation of the
product. Probiotics were predominantly recommended for
oral administration (97.1%, 101/104). Of the four vaginal
products available, two were intended for oral administra-
tion, one was for both oral and vaginal administration and
one for vaginal dosing only, and all were stored at room
temperature.
Two-thirds (64.4%, 67/104) of the surveyed products
were manufactured in SA [88.1% (59/67) of shelf
Fig. 2 Bacterial distribution in probiotics. a Constituting organisms. Bacterial species contained in probiotics belonged to the genera Lactobacillus
with 15 species, Bifidobacterium with 8 species, Streptococcus thermophilus, Enterococcus mundtii and Propionibacterium shermanii. The
yeast Saccharomyces was represented with two species. b Health claims and association with bacterial composition. Each product was
grouped into one health category as described above and bacterial strains were listed. For the complete figure see Additional file 1:
Figure S1.1 and Additional file 2: Figure S1.2
Happel et al. BMC Women's Health  (2017) 17:7 Page 5 of 10
products versus 11.9% (8/67) of refrigerated products].
The total of 104 products were produced by 39 manu-
facturers, of which 27 (69.2%) were based in SA, mainly
in Johannesburg (12/27), Pretoria (6/27) and Cape Town
(6/27). Of the four vaginal products, two were manufac-
tured in SA (Reuterina™ Femme, Bioflora Vagiforte®
Plus), one in Canada (Provacare® Probiotic Vaginal Care)
and one in the US (UltraFlora® Women’s).
Aside from bacteria, most products contained add-
itional ingredients, such as vitamins, minerals, enzymes
or fruit extracts. Common enzymes included were di-
gestive enzymes including amylase, protease, invertase,
malt diastase, lipase, cellulose or lactase. A few products
(8/104, 7.7%) contained folic acid (vitamin B9), which is
important for nucleotide synthesis in humans and
bacteria but cannot be synthesized by humans. Some
bacteria synthesize folate, including many Bifidobacter-
ium spp. but only a few Lactobacillus spp. and thus, it
needs to be ingested [44]. Similar percentages of prod-
ucts contained thiamine (vitamin B1), a coenzyme in the
metabolism of sugars and amino acids, and riboflavin
(vitamin B2) or nicotinamide (vitamin B3) that are both
needed for oxidation-reduction reactions [45]. Those
products also included pantothenic acid (vitamin B5),
which is a cofactor for the synthesis and metabolism of
proteins, carbohydrates and fats, vitamin B6, a coenzyme
for amino acid, glucose and lipid metabolism, and biotin
(vitamin B7) that is a coenzyme for carboxylase enzymes
needed for the synthesis of some amino acids, fatty acids
and gluconeogenesis [45].
The majority of products (67.3%) did not contain pre-
biotics. In those that did, the most common were
fructo-oligosaccharides and inulin, which are both indi-
gestible carbohydrates that reach the intestine intact
where they encounter Lactobacillus and Bifidobacterium
spp., which are able to metabolize and transport these
compounds [46].
Claims of probiotics for vaginal health
We found four probiotics that made explicit claims on
the package insert for vaginal health that were not refer-
enced. None of the four products had MCC or FDA
approval and they were not marketed as complementary
medicine or as medicines. Reuterina™ Femme claims to
help maintain a healthy vaginal flora and prevent uro-
genital infections and BV. Its dosage can be in-
creased from one to two capsules daily and there are no
known symptoms when overdosed, but no references
were provided to support this statement. The package
insert seems to contradict the claims on the outer pack-
ing as it states that this product is not intended to treat,
cure or prevent disease. Provacare® Probiotic Vaginal
Care is classified as nutritional substance and claims to
restore vaginal flora balance and maintain the ideal pH.
It also claims to assist in the relief of symptoms of burn-
ing, stinging and vaginal discharge. Bioflora Vagiforte®
Plus claims to restore and maintain the normal vaginal
flora by controlling the overgrowth of pathogenic micro-
organisms in the GIT and preventing their transfer to
the urogenital tract. High dose treatment is stated to
prevent the development of BV and candidiasis. The
dose is one oral capsule daily for five days and then one
tablet vaginally daily for the next five days. UltraFlora®
Women’s is taken orally once to twice daily and is
claimed to restore and maintain a healthy vaginal
microflora, and reportedly reduces pathogenic bacteria
and yeasts. Further, UltraFlora® Women’s claims to as-
sist treatment of BV in conjunction with antibiotics
when taken twice daily for at least seven days 2–3 h be-
fore or after the antibiotics. Those statements have not
been evaluated by the FDA.
Cost of probiotics
The median cost per probiotic capsule or tablet in this
study was USD 0.45 [currently equivalent to 6.30 South
African Rand (ZAR)], ranging from USD 0.13–3.29
(ZAR 1.80–46.00). Probiotic prices did not differ statisti-
cally significantly between Cape Town and Durban
(mean of ZAR 6.50 vs. ZAR 6.00), nor when comparing
probiotics manufactured locally to those that were
imported, or probiotics stored on the shelf to those re-
quiring refrigeration. Instead, prices of products differed
according to manufacturer with products from Meta-
genics®, Bioflora CC, Viridian Nutrition and Vibrant
Health® being more expensive (mean ZAR 22.40, USD
1.60 per capsule/tablet) when compared to those from
other manufacturers evaluated in this study (mean: ZAR
4.60, USD 0.33 per capsule/tablet; p < 0.0001). Given that
>60% of households of Cape Town and Durban metrop-
oles earned < USD 445.00 (ZAR 6367) per month in 2011
(Census 2011, http://www.statssa.gov.za), the cost of one
treatment course per individual of any of the vaginal pro-
biotics publically available in South Africa would use up
1.6–4.9% of monthly income.
Discussion
The commensal microbiota in the female genital tract is
important to protect women against STIs, including
HIV. BV is associated with increased risk of infection
with HIV [26], other STIs [22, 23], and reproductive
complications [19–21]. Management of BV is challen-
ging as it is frequently asymptomatic and thus, the ma-
jority of cases go undiagnosed [27]. Further, antibiotic
treatment usually fails in the long-term, with recurrence
rates of ~30% within three months of treatment and
~50% within six months [29]. As BV is related to an often
recurrent deficiency of appropriate commensal microor-
ganisms, adjunctive probiotic therapy could provide
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significant benefit in ensuring maintenance of a healthy
biome in women treated for BV.
The aim of this survey was to determine the availabil-
ity of vaginal probiotics in South Africa, a region with
high BV and HIV burden in young women. We identi-
fied 104 products available in Cape Town and Durban,
with more products marketed in Cape Town than in
Durban. Although there were fewer stores in Durban
selling probiotics, these two major cities do not differ in
population size, gross domestic product (GDP), average
income, unemployment rates or medical aid coverage
(http://www.statssa.gov.za), proxies for social-economic
status and general health in both cities. Factors contribut-
ing to this discrepancy in probiotic availability are likely to
be complex, but may include cultural and ethnic differ-
ences in the populations, and differences in traditional,
complementary and alternative medicine use [47].
The predominant indication for probiotics in South
Africa is for GIT health with only four products being
marketed for vaginal health, illustrating a huge discrep-
ancy in product availability given BV rates of up to 58%
in South Africa [25]. Most of the bacterial strains con-
tained in the four vaginal probiotics identified in this
study were not common colonizers of the lower repro-
ductive tract. For instance, B. longum ssp. longum and B.
bifidum are commensal in the GIT [48], while L. acid-
ophilus, L. reuteri and L. rhamnosus primarily colonize
the GIT [49], but also have been isolated from the fe-
male genital tract [41].
While the efficacy of probiotics still needs to be
proven in clinical trials, the development of vaginal pro-
biotics should, as a reasonable starting point, contain
species that are frequently commensals of the healthy
vaginal tract, such as L. crispatus, L. gasseri, L. jensenii,
L. vaginalis and L. iners. The efficacy of probiotic combi-
nations of vaginal commensal bacterial species, strains
and dose along with adjunctive antibiotic use to treat BV
and prevent its recurrence needs also to be evaluated.
The most common bacterial species found overall in
probiotics in the South African market were L. acidoph-
ilus, L. rhamnosus, B. longum ssp. longum, B. animalis
ssp. lactis, B. bifidum and L. plantarum. Some reasons
cited for the use of L. acidophilus strains in probiotic
formulations include that it is stable in products, resist-
ant to GIT bile, tolerant to low pH, and adherent to
human colonocytes in cell culture [50–53]. In addition,
they produce antimicrobial substances and contain lac-
tase activity, meeting the criteria needed for an effective
probiotic [54]. Similar characteristics have been de-
scribed for all the above-mentioned Lactobacillus and
Bifidobacterium spp. commonly found in probiotics
[55–57]. Additionally, these probiotic strains do not
compete with each other for essential nutrients and
therefore, can be combined in products [56].
Bifidobacterium spp. are able to produce acetic acid that
reduces yeast growth [58], which may be a reason why it
is contained in some vaginal probiotics, although these
species are much less common in the female genital
tract than Lactobacillus spp. [59].
In addition to Lactobacillus and Bifidobacterium spp.,
other species were less commonly found in probiotics in
SA, including S. boulardii, S. cerevisiae and E. mundtii.
The non-pathogenic yeast strains S. boulardii and S. cer-
evisiae may regulate intestinal microbial homeostasis
[60], interfere with the ability of pathogens to colonize
and infect the mucosa [61–63], modulate immune re-
sponses [64–66], stabilize the gastrointestinal barrier
function and induce absorption of nutrients [67]. The
inclusion of E. mundtii in probiotics is controversial as it
is thought to be marginally virulent, with reports of en-
dophthalmitis (inflammation of the intraocular cavities)
published [68, 69] and it is not considered safe by the
FDA [69].
In the USA, the FDA applies a complex framework of
regulation to validate manufacturers’ claims for the
products they market [70]. In this framework, a health
claim is “any claim made on the label or in labelling of a
food, including a dietary supplement, that expressly or
by implication, including ‘third party’ references, written
statements, symbols, or vignettes, characterizes the rela-
tionship of any substance to a disease or health related
condition” [71]. In the case of vaginal probiotics, this
could possibly be a reduction in the risk of incurring BV
in a healthy population. While regulatory bodies (includ-
ing the FDA and the South African MCC) are more con-
cerned with product safety than misleading claims,
sound scientific approaches need to be used to demon-
strate the health benefits of probiotics such as dose-
response relationship [72]. Previous studies have shown
poor correlation between label claims and actual pro-
biotics content [73, 74], so post-market surveillance
should be mandatory to demonstrate health benefits
related to probiotics.
This survey had some limitations. The exact shelf life-
time could not be determined because only the expiry
date and date of survey, but not the date of production
were captured. We did not look at any other cities in the
country but restricted our study to two of the larger
cities, and only looked at one centre per district within
these cities.
Conclusions
This study provides a strong rationale for the develop-
ment and clinical evaluation of additional probiotics for
vaginal health, as these products are underrepresented
in the South African probiotic market. Adjunctive ther-
apy with probiotics targeting young women with BV in
regions with highest BV and HIV incidence has the
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potential to provide considerable benefit. A cost analysis
of the products in our study confirmed that the prices of
these probiotics still represent a considerable barrier in
their limited uptake in the segments of the population
most in need. This highlights the need for the development
and testing of cheaper, alternative products, which will
have the added benefit of being tailor-made for the South
African population. The increased availability of vaginal
probiotics represents an intervention with significant
potential that can help decrease the burden of BV in the
South African community.
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